Novel Pneumococcal Conjugate Vaccine Immunogenic in Phase 3 Trials
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Study authors assessed pneumococcal urinary antigen testing’s use in identifying patients for broad-spectrum antibiotic de-escalation, providing an opportunity for improved antimicrobial stewardship.
Researchers linked the use of 2 hypertension drug classes to lower mortality for those hospitalized with flu and pneumonia.
Pneumomediastinum, although a rare phenomenon, is more prevalent in patients with COVID-19 compared with historical patients with adult respiratory distress syndrome.
Patients with severe COVID-19 pneumonia had improved prognosis after receiving a short course of methyl-prednisolone pulses during the second week of disease.
Approximately 7% of pneumonia cases acquired in the intensive care unit can be classified as Staphylococcus aureus intensive care unit pneumonia.
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
Researchers compared HAdV-3 with HAdV-7 replication kinetics and host response in ex vivo human lung tissue cultures.
For patients with heart failure, influenza and pneumococcal vaccinations are associated with lower in-hospital mortality.
The aim of this study was to evaluate the invasive disease potential of non-PCV13 serotypes after implementation of this vaccine.